``The company has $233 million in cash, only $79 million in debt, and is trading at a little over two times its book value per share. It has a trailing P/E of only 5 and a forward P/E of just 8, and the company was finally able to become profitable in 2005, on the strength of Vancocin. Generics, if they`re ever even approved, will not appear on the market for at least two years, and ViroPharma has announced its intention to vigorously defend its patents. Considering the hypervirulency of the new bacteria, it seems unlikely that the FDA would follow through.

Moreover, while Vancocin is the biotech`s sole product right now, it has two other drugs in its pipeline: Maribavir, which it acquired from GlaxoSmithKline (NYSE: GSK) in 2003, is used to treat cytomegalovirus, a common virus in the herpes family that is found worldwide; and HCV-796, with which it entered into a partnership with Wyeth (NYSE: WYE) in 1999 to target hepatitis C. Considering the amount of cash it has on hand from Vancocin, it could also always buy into another cash-producing drug -- should generics prove formidable.

The sell-off is definitely overwrought here, and investors would do well to look a little closer at this promising biotech....

If you find another company with similar numbers, please do

not hesitate to post it here...

Good Luck to all...

Gil...

P.S. to TK...

No Cal. did not ``invent`` free speech. The ``Free Speech Movement``, however, was definitely a lauable effort by a valiant student body of a great University to wake up a sleeping Nation to the fact that FREE SPEECH needed to be exercised if it was to have any meaning at all... And that my friend is a FACT that even you will have to admit...

Gil...